| Trial | Updated / Type |
Status | Phase | Were Results Reported |
Reported Actual Enrollment |
(MeSH) Terms |
Why Stopped
Limitations And Caveats |
Annotator decisions |
|---|---|---|---|---|---|---|---|---|
| NCT00427934 Details | 2014-11-05 Interventional | 2 | 128 | Maraviroc Arthritis Arthritis, Rheu… | See Detailed Description. - | |||
| NCT01172756 2010-018436-41 Details | 2014-11-04 Interventional | 2 | 39 | Riociguat Hypertension Hypertension, P… Ventricular Dys… Ventricular Dys… | Recruitment was only stopped after the statistical power of the study was reached and the study
objectives could be met despite the premature discontinuation. - | |||
| NCT00753220 Details | 2014-11-04 Interventional | 1/2 | 7 | Cyclophosphamid… Prostatic Neopl… Prostate Cancer | Withdrew the IND with the FDA. - | |||
| NCT00300885 2005-005245-19 Details | 2014-11-04 Interventional | 3 | [1 Refs] | 926 | Albumin-Bound P… Carboplatin Paclitaxel Sorafenib Carcinoma, Non-… Lung Neoplasms Carcinoma, Non-… | Based on the results of the interim analysis, it was determined that the study would not meet
its primary efficacy endpoint and the study was terminated early. Based on the results of the interim analysis, it was determined that the study would not meet its primary efficacy endpoint and the study was terminated early. The planned biomarker analysis was suspended due to early termination. | ||
| NCT01853176 Details | 2014-11-02 Interventional | 4 | 4 | Bupivacaine Pain, Postopera… | required documentation too onerous Trial terminated prior to any meaningful patient accrual so no analysis performed. | |||
| NCT01227512 Details | 2014-10-30 Interventional | 3 | 124 | Tolvaptan Hyponatremia Inappropriate A… Dilutional Hypo… | Recruitment challenges and results of interim futility analysis, which showed less than likely
to achieve primary endpoint goal-length of hospital stay. - | |||
| NCT01196104 Details | 2014-10-30 Interventional | 3 | 39 | Insulin Insulin Aspart Insulin Glargin… Insulin, Globin… Diabetes Mellit… Type 2 Diabetes | For Business Reasons - Early termination of trial leading to small numbers of subjects analyzed. | |||
| NCT00747006 Details | 2014-10-30 Interventional | 2 | 18 | Insulin Lispro Diabetes Mellit… Diabetes Mellit… Diabetes Mellit… Respiratory Asp… | Business reasons - Early termination of trial leading to small numbers of subjects analyzed. | |||
| NCT00918385 Details | 2014-10-29 Interventional | 2 | 57 | Dasatinib Nilutamide Prostatic Neopl… Prostate Cancer | Permanent closure of trial to further accrual based on IDE disapproval - | |||
| NCT00446589 Details | 2014-10-29 Interventional | 4 | 19 | Ibandronic Acid Teriparatide Osteoporosis | due to financial problems - | |||
| NCT00446329 Details | 2014-10-29 Interventional | 4 | 15 | Cinacalcet Hyperparathyroi… Hyperparathyroi… Neoplasm Metast… Secondary Hyper… | due to financial problems - | |||
| NCT00535262 Details | 2014-10-28 Interventional | 4 | 3 | Selegiline Bipolar Disorde… Depression Depressive Diso… Bipolar Depress… | Current lack of medication support. Early termination due to lack of financial support; only 3 participants were entered into the study; no data was analyzed. | |||
| NCT01313663 Details | 2014-10-27 Interventional | 2 | 20 | Pemetrexed Carcinoma, Non-… Lung Neoplasms Small Cell Lung… Lung Cancer, Sm… | - - | |||
| NCT00619229 2005-005686-11 Details | 2014-10-27 Interventional | 3 | 37 | Alprostadil Macular Degener… | Interim Analysis: Optimization of study design required. - | |||
| NCT02273544 Details | 2014-10-24 Interventional | 1 | 16 | Aspirin, Dipyri… Healthy | - - | |||
| NCT01848106 2013-001384-23 Details | 2014-10-23 Interventional | 3 | 3232 | Bivalirudin Coronary Artery… Coronary Diseas… Myocardial Isch… | Clinical Hold - | |||
| NCT00548717 Details | 2014-10-21 Interventional | 2 | 15 | Bortezomib Mycophenolic Ac… Sirolimus Graft vs Host D… Graft-vs-Host D… | First two patients enrolled after trial reopened, developed grade III-IV acute GVHD and
subsequently passed away. Early termination leading to small numbers of subjects analyzed. Results are reported for transparency only, and should not be used to extrapolate significant conclusions. | |||
| NCT00881504 Details | 2014-10-20 Interventional | 2 | 9 | Bevacizumab Biliary Tract N… Biliary Tract C… | It was not possible to get insurance companies to cover bevacizumab. - | |||
| NCT01342016 Details | 2014-10-17 Interventional | 3 | 84 | Leflunomide Prednisone Tacrolimus Lupus Nephritis Nephritis | Due to safety concern of active control drug - | |||
| NCT00682656 Details | 2014-10-17 Interventional | 2/3 | 48 | Azithromycin Meglumine Antim… Leishmaniasis Leishmaniasis, … Cutaneous Leish… | Efficacy issues on test arm - |